Comorbidities in Androgenetic Alopecia: A Comprehensive Review

Abstract

Androgenetic alopecia is the most common form of hair loss, affecting 85% of men and 40% of women. Androgenetic alopecia is a disease caused by multiple factors, such as genetics, hormones, and systemic diseases; however, the exact cause remains undetermined. Recent studies have found that it is associated with a high incidence of endocrine diseases and other comorbidities. It may not only be a skin disease but also an early signal of underlying systemic diseases. Effective management requires timely diagnosis and treatment initiation. However, in current clinical practice, androgenetic alopecia is still not fully understood or treated. Recognizing the true physical, social, and emotional burden of androgenic alopecia, as well as its associated comorbidities, is the first step in improving the prognosis of affected patients. This review aimed to gather the known pathological factors and provide a reference for clinical physicians to understand androgenetic alopecia and its comorbidities in depth, thereby enabling early recognition of the underlying systemic diseases and providing timely treatment.

Prevalence and Clinical Characteristics of Androgenetic Alopecia in Nepalese Patients: A Cross-sectional Observational Study

“…There are studies depicting varied association of AGA with systemic diseases. 19 Systemic diseases such as metabolic syndrome which includes hypertension, diabetes and obesity have been shown to be present concomitantly in patients with AGA. 19 Our study showed co-existence of systemic disease such as coronary artery disease in 3 patients and one patient with AGA with prostate cancer had completed his cancer therapy.…”

“…19 Systemic diseases such as metabolic syndrome which includes hypertension, diabetes and obesity have been shown to be present concomitantly in patients with AGA. 19 Our study showed co-existence of systemic disease such as coronary artery disease in 3 patients and one patient with AGA with prostate cancer had completed his cancer therapy. Patients should be screened for comorbid concomitant metabolic syndrome, for early metabolic control and prevention of hazardous complications thereof.…”

Endocrine and metabolic comorbidities in primary cicatricial alopecia: A nationwide population‐based study

“…Comorbidities associated with PCA remain largely unknown. 20,21 Owing to its low incidence, most retrospective studies on PCA have had small sample sizes, which provide insufficient information for identification of comorbidities. 11,[22][23][24] A recent, large, populationbased study showed that LPP is significantly associated with metabolic syndrome (OR 10.11, P < 0.001).…”

“…Comorbidities associated with PCA remain largely unknown 20,21 . Owing to its low incidence, most retrospective studies on PCA have had small sample sizes, which provide insufficient information for identification of comorbidities 11,22–24 .…”

Hair loss after SARS-CoV2 Infection

“…Przez to wielu badaczy wysnuło tezę, która mówi, że występowanie łysienia androgenowego jest czynnikiem ryzyka zachorowania na Covid -19, lub jego cięższego przebiegu. [22][23] Związek między występowaniem łysienia androgenowego, a ciężkim przebiegiem infekcji koronawirusem, postanowiono nazwać "objawem Gabrina", na cześć pierwszego amerykańskiego lekarza, który zmarł w wyniku ciężkiego przebiegu Covid-19 i od lat chorował na łysienie androgenowe, jednak część naukowców nie jest przekonanych, czy to odpowiedni przejaw wyrazu uznania. [23][24] V Wnioski Wybuch pandemii 3 lata temu zmienił cały świat, mimo upływu tego czasu dalej nie jest dobrze poznana choroba, zdefiniowany został "long Covid" oraz zespół postcovidowy, jednak dalej nie wiadomo jaki wpływ na organizm będzie miał koronawirus w perspektywie kilku lat.…”